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1040-84 Thrombolytic Therapy but Not Primary Angioplasty Is 
Associated With an Early Hazard in Patients >75 Years 
Old With Acute Myocardial Infarction: Results of the 
PPRIMM75 Registry 
Hector Buena, Manuel Martinez-Selles. Esther Perez-David, Ramon Lopez-Palop, 
Hospital General Universitario “Gregorio Maranon”, Madrid, Spain 
Background. The efficacy and safety of thrombolytic therapy (TT) in patients >75 years 
old is still controversial. 
1040-82 Long-Term Statin Use and Psychological Well-Being in 
the Elderly 
Yinong Young-Xu, Arnold Ghan. James K. Liao. Shmuel Ravid, Charles M. Elan, Lawn 
Cardiovascular Research Foundation, Brookline. MA, Harvard School of Public Health, 
Boston, MA 
Background: The effect of long-term statin use on psychometric measures was studied 
in a cohort of elderly patients with coronary disease. 
Methods The exposure of interest was long-term statin use and the outcomes of interest 
were depression, anxiety, and hostility as measured annually with the Kellner Symptom 
Questionnaire. The Generalized Estimating Equation and multiple logistic regression 
estimated the odds ratios (ORs) and 95% confidence intervals (Cl), to represent the 
association between statin use and nsk of abnormal depression, anxiety. and hostility 
scores. 
Results 606 study subjects (average age 67, 80% male) mean follow-up 4 years, maxi- 
mum 7 years were followed. Comparing the 140 patients with continuous statin use and 
231 who did not use cholesterol-lowering drugs, statin use was associated with lower risk 
of abnormal depression scores (OR, 0.64; 95% Cl, 0.43 - 0.93), anxiety scores (OR, 
0.62; 95% Cl, 0.43-0.90). and hostility scores (OR, 0.65; 95% Cl, 0.45-0.93) after adjust- 
ment for confounders. NO association was found when 219 patients with intermittent sta- 
tin use and non-&tin cholesterol-lowering drug use were compared with 231 patients 
who did not use cholesterol-lowering drugs. The risk of an abnormal psychometric score 
decreased over time. The beneficial psychological effects of the statins appeared to be 
independent of its cholesterol-lowering effect. Conclusions Long-term statin use is 
associated with reduced risk of anxiety. depression, and hostility in the elderly. 
Methods. To assess the results of TT in older patients, we analyzed the In-hospital, 6- 
month and 24-month mortality in a cohort of 516 consecutive patients admined to a CCU 
for a first-time ST-segment/LBBB AMI enrrolled in the PPRIMM75 (Pron6stico del 
PRimer lnfalto de Miocardio en Mayores de 75 adios) Registry according to the type of 
treatment received: no reperlusion (n=314). TT (n=118) or primary angioplasty (PA, 
ll=84). 
Results. Patients treated with TT were admined earlier (median: 3 vs. 5 hours), nwrs fre- 
quently in Killip class I (77% vs 65%) and had a higher LVEF than non-reperfused 
patients (all pc.01). Compared with patients treated with PA, those who received TT had 
a significantly lower proportion of diabetes (27% vs 45%), anterior infarcts (42% vs 57%), 
LVEF < 0.31 (10% vs 24%) and Killip class I (23% vs 46%). The crude in-hospital mortal- 
ity was 33.8% in non-reperiused patients, 28.8% in those treated with TT and 29.8% with 
PA. After excluding patients arriving in shock, the figures were: 28%, 27.4% and 17.9% 
respectively. The graph shows the odds ratio of in-hospital mortality and the hazard 
ratios for 6. and 24-month mortality for reperfused patients compared with non-reper- 
fused patients after adjustment for baseline differences. 
Conclusion. Thrombolytic therapy may be associated with an early increase in morlality 
in elderly patients with AMI, an effect not observed with PA. 
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t 040-83 Outcomes of an Elderly Population Undergoing 
Maximal Medical Therapy 
Thomas B. Grabovs, Yinong Young-X& Charles M. Blatt, Shmuel Ravid, Brian Bikhik, 
Low Cardiovascular Research Foundation, Brookline, MA 
Background: ClInical trials among patients with coronary heart disease (CHD) have tra- 
ditionally excluded patients greater than 75 years of age and certainly those over 80 
years. Methods We evaluated outcomes among a geriatric population a75 and a80 
years (76% males) as part of a larger CHD database. Twenty-two percent (166) were 
over age 75 at entry and 417 (54%) over age 75 at the time of data analysis.Results: At 
a mean follow up of 64.4 months, the average age of those over 80 years was 135.5 
years. Patients underwent traditional noninvasive cardiac evaluation and received maxi- 
mal medical therapy. Average ejection fraction was 59%. Over the follow-up period, 160 
(38%) met criteria for coronary intervention (Cl), though only 52 (21%) were actually 
referred for Cl. The criterion was principally defined as a significant change in the pattern 
of angina. The annualized rate of myocardial infarctton was 2.4% and annualized cardiac 
mortality 1.3%. Conclusions These data emphasize that a geriatric population >age 75 
years undergoing maximal medical therapy for their CHD have excellent long-term out- 
comes and that utilizing data from clinlcal trials among a younger CHD population may 
be extrapolated to geriatric and octogenarian populations with intact left ventricular func- 
tion. Furthermore, changes in angina1 pattern remain an important and valid criterion for 
Cl in the elderly population. 
1040-85 National Trends of Lower Target Intensity Among 
Elderly Patients Taking Warfarin: The Anticoagulation 
Consortium to Improve Outcomes Nationally (ACTION) 
Study 
sy, Susan Regan, Robyn McClelland. Sherry Stewart, Elaine M. Hylek, 
Mayo Clinic, Rochester, MN, Massachusetts General Hospital, Boston, MA 
Background. Since risk of warfarin-related hemorrhage increases with age and INR. 
some physicians use a lower INR target for older patients (80 years or older) with atrial 
fibrillaton (AF). We assessed use and impact of lower target ranges in a national cohort 
of patients taking warfarin. Methods. Antkxagulation clinics were recruited across the 
U.S. from 1999-2001. Physician-assigned INR target ranges were analyzed for AF, 
stroke, or prosthetic valve. The % of subtherapeutic INRs for patients with a lower target 
range was compared to the 2-3 range, or 2.5-3.5 for valves. INRs from the first 2 months 
were excluded. Results. 6,706 patients were enrolled from 100 clinics in 38 states accu- 
mulating 5,929 person-years. 44% of patients were female; and 22% were age 80 or 
over. Increasing age was asscclated with lower INR target (p < O.OOOl)‘(table). For 
stroke or AF, only 5% of patients overall were assigned an INR target range < 2-3. How- 
ever, patients with lower targets were at greatly increased risk for subtherapeutic INRs 
compared to those in the standard range. For patients age 80 or over vs. < 80 years: for 
AF, 40% of INRs were < 2 vs. 21%; stroke, 43% vs. 19%; prosthettc valve, 52% of INRs 
were less than 2.5 vs. 28%. and 19% vs. 8% were less than 2.0 (p r; 0.0001). Conclu- 
sion. Lower INR targets are more frequently used I” older patients. Given the Increased 
exposure to INRs less than 2, more data are needed to be certain of the risk vs. benefit in 
this group. 
Use of Lower INR Target Range Across Age 
Atrlal Fibrillation Stroke n=498 Prosthetic Valve 
n=3,242 n=745 
Age. yrs Upper INR target limit Upper INR target limit Upper INR target limit 
less than 3 less than 3 less than 3.5 
60.69 2% (14/678) 4% (5/l 40) 9% (24/256) 
70-79 4% (5811528) 5% (12/234) 15% (521357) 
Greater than 7% (70/l 036) 10% (12024) p=.O37 27% (35/132)’ 
or=to80 
